Recent IPO activity and the near-term pipeline remain the dominant drivers of trader sentiment for U.S. listings before 2027. Multiple small-to-mid-sized offerings have priced or are slated for late October and November 2026, including Lycia Therapeutics, which raised $318 million at the top of its range on October 22, alongside biotech and industrial names. Broader market conditions have softened, with Nasdaq noting fewer new listings amid elevated 30-year Treasury yields near multi-decade highs, recent Fed rate hikes responding to inflation pressures, and selective investor demand that prompted delays or withdrawals by larger AI and data-center candidates. While the overall window has narrowed, the steady flow of filings and pricings supports continued activity through year-end, though high-profile names like Anthropic face execution risk that could push them into 2027.